Assembly Biosciences, Inc.’s ASMB share price has dipped by 10.07%, which has investors questioning if this is right time to ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Allurion Technologies (ALUR – Research Report), ...

Since entering the Bengaluru market in 2013, Arvind SmartSpaces has expanded its footprint with 12 projects, of which six ...

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q4 earnings results on Wednesday, March 26th, before market open. The consensus EPS Estimate is -$2.94 (+27.6% Y/Y) and the consensus ...

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40 th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical ...

Monogram Technologies Inc.’s MGRM share price has dipped by 10.69%, which has investors questioning if this is right time to ...

Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline - - Interim Phase 1b proof-of-concept data, including initial efficacy ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hyperfine (HYPR – Research Report) and Monogram Orthopaedics ...

Overview: Monogram Technologies Inc. specializes in creating product solution architecture for patient-optimized orthopedic implants and has a market cap of $79.95 million. Operations: Monogram ...

Overview: Monogram Technologies Inc. specializes in creating product solution architecture for patient-optimized orthopedic implants and has a market cap of $79.95 million. Operations: Monogram ...

Analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for shares of Monogram Orthopaedics in a research report issued on Thursday, March 13th. Zacks Small Cap analyst T.

Stock analysts at Roth Capital upped their FY2028 earnings per share (EPS) estimates for Monogram Orthopaedics in a research report issued on Thursday, March 13th. Roth Capital analyst J. Wittes now ...